#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3818	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2488	451.5	0	.	n	.	0	C207T	SNP	207	207	C	633	633	T	531	T,C,A	223,240,3	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3818	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2488	451.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1610	1610	C	522	C,A	464,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3818	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2488	451.5	0	HET	.	.	.	C1450T	.	1450	1450	C	1876	1876	C	571	C,T	397,128	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3818	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2488	451.5	0	HET	.	.	.	C451T	.	451	451	C	877	877	C	535	C,T	240,235	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3818	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2488	451.5	0	HET	.	.	.	T84TCGGGTGGCG,TCG	.	84	84	T	510	510	T	551	TCGGGTGGCG,TCG	383,141	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5910	23S	2890	2890	99.9	23S.l6.c17.ctg.1	4407	399.7	0	.	n	.	0	T695C	SNP	695	695	T	1271	1271	C	450	C,T	396,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5910	23S	2890	2890	99.9	23S.l6.c17.ctg.1	4407	399.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2547	2547	C	526	C,T,A	480,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5910	23S	2890	2890	99.9	23S.l6.c17.ctg.1	4407	399.7	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3173	3173	T	530	T	480	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5910	23S	2890	2890	99.9	23S.l6.c17.ctg.1	4407	399.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2621	2621	A	533	A	480	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	476	folP	855	855	100.0	folP.l15.c4.ctg.1	2221	64.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1419	1421	AGC	104;103;102	A;G;C	92;94;88	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1060	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3659	85.7	1	SNP	p	S91F	1	.	.	271	273	TTC	697	699	TTC	116;115;116	T;T;C	106;106;107	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1060	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3659	85.7	1	SNP	p	D95G	1	.	.	283	285	GGC	709	711	GGC	118;119;118	G;G;C	109;110;109	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1060	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3659	85.7	1	SNP	p	G95N	0	.	.	283	285	GGC	709	711	GGC	118;119;118	G;G;C	109;110;109	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	496	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1982	75.2	1	SNP	p	G45D	0	.	.	133	135	GGC	852	854	GGC	127;127;127	G;G;C	115;117;119	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	310	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1538	60.5	0	.	n	.	0	A197.	DEL	197	197	A	844	844	A	116	A	104	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1040	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3448	90.0	1	SNP	p	D86N	0	.	.	256	258	GAC	879	881	GAC	104;103;103	G;A;C	94;94;94	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1040	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3448	90.0	1	SNP	p	R87I	0	.	.	259	261	CGT	882	884	CGT	103;103;103	C;G;T	97;94;91	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1040	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3448	90.0	1	SNP	p	R87W	0	.	.	259	261	CGT	882	884	CGT	103;103;103	C;G;T	97;94;91	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1040	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3448	90.0	1	SNP	p	S87R	1	.	.	259	261	CGT	882	884	CGT	103;103;103	C;G;T	97;94;91	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1040	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3448	90.0	1	SNP	p	S88P	0	.	.	262	264	TCC	885	887	TCC	104;104;104	T;C;C,G	93;96;94,1	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	986	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3099	95.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1764	1766	GGC	118;118;119	G;G;C	107;105;105	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	928	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2833	97.7	1	SNP	p	A311V	0	.	.	931	933	GCC	1462	1464	GCC	133;133;133	G,T;C;C	121,1;118;120	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	928	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2833	97.7	1	SNP	p	I312M	1	.	.	934	936	ATG	1465	1467	ATG	133;133;133	A;T;G	122;119;121	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	928	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2833	97.7	1	SNP	p	T316P	0	.	.	946	948	ACC	1477	1479	ACC	135;137;135	A;C;C	123;124;124	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	928	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2833	97.7	1	SNP	p	V316T	1	.	.	946	948	ACC	1477	1479	ACC	135;137;135	A;C;C	123;124;124	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	928	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2833	97.7	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1978	1980	ACC	121;122;123	A;C;C	108;108;114	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	928	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2833	97.7	1	SNP	p	A501P	0	.	.	1501	1503	GCG	2032	2034	GCG	126;124;125	G;C;G,A	113;107;106,1	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	928	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2833	97.7	1	SNP	p	A501V	0	.	.	1501	1503	GCG	2032	2034	GCG	126;124;125	G;C;G,A	113;107;106,1	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	928	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2833	97.7	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2155	2157	GGT	103;103;103	G;G;T	92;91;93	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	928	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2833	97.7	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2164	2166	AGC	100;100;101	A;G,T;C	89;93,1;90	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	928	penA	1746	1746	100.0	penA.l6.c17.ctg.1	2833	97.7	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2182	2184	CCG	104;105;105	C;C;G	87;92;87	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1182	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3488	101.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1853	1855	CCG	99;99;98	C;C,T;G	87;82,1;91	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	600	porA	1146	1146	99.91	porA.l15.c4.ctg.1	2205	81.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	750	750	C	97	C	90	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	130	porB1a	984	297	91.03	porB1a.l15.c30.ctg.1	1097	27.8	0	.	p	.	0	H217N	NONSYN	649	651	CAT	823	825	AAT	20;20;20	A;A;T	16;17;16	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	130	porB1a	984	297	91.03	porB1a.l15.c30.ctg.1	1097	27.8	0	.	p	.	0	D218N	NONSYN	652	654	GAT	826	828	AAT	20;20;20	A;A;T	16;16;16	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	130	porB1a	984	297	91.03	porB1a.l15.c30.ctg.1	1097	27.8	0	.	p	.	0	V226A	NONSYN	676	678	GTA	850	852	GCA	18;18;18	G;C;A	16;15;16	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	130	porB1a	984	297	91.03	porB1a.l15.c30.ctg.1	1097	27.8	0	.	p	.	0	.	MULTIPLE	700	702	ACT	873	875	GTA	15;15;15	G;T;A	14;14;14	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	130	porB1a	984	297	91.03	porB1a.l15.c30.ctg.1	1097	27.8	0	.	p	.	0	N237fs	FSHIFT	709	709	A	882	882	A	15	A	14	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	694	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	1914	107.3	0	.	p	.	0	R144Q	NONSYN	430	432	CGG	927	929	CAG	132;131;131	C;A;G	128;125;125	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	694	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	1914	107.3	0	.	p	.	0	G210R	NONSYN	628	630	GGA	1125	1127	AGA	138;137;137	A;G;A	126;122;121	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	694	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	1914	107.3	0	.	p	.	0	S217G	NONSYN	649	651	AGT	1146	1148	GGT	136;136;137	G;G;T,G	125;124;127,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	694	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	1914	107.3	1	SNP	p	G120K	1	.	.	358	360	AAG	855	857	AAG	150;149;149	A;A;G,T	133;133;135,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	694	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	1914	107.3	1	SNP	p	A121N	1	.	.	361	363	AAC	858	860	AAC	150;151;151	A,G;A;C,A	133,1;134;132,1	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	694	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	1914	107.3	1	SNP	p	N121D	0	.	.	361	363	AAC	858	860	AAC	150;151;151	A,G;A;C,A	133,1;134;132,1	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2274	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5434	125.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	366	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1686	64.8	1	SNP	p	V57M	1	.	.	169	171	ATG	808	810	ATG	132;131;132	A;T;G	118;118;120	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
